Literature DB >> 28294301

Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitis-like T-cell lymphoma.

Zhaoming Li1,2, Lisha Lu1,3, Zhiyuan Zhou1,3, Weili Xue1,3, Yingjun Wang1,3, Mengyuan Jin1,3, Yajuan Qiu1,2, Wei Sun4, Xuefei Fu4, Xudong Zhang1,2, Yu Chang1,2, Feifei Nan1,2, Jiaqin Yan1,2, Guannan Wang5, Zhenchang Sun1,2, Xiaorui Fu1,2, Ling Li1,2, Xin Li1,2, Xinhua Wang1,2, Jingjing Wu1,2, Lei Zhang1,2, Mingzhi Zhang1,2.   

Abstract

Entities:  

Keywords:  PI3K/AKT/mTOR pathway; epigenetic modifiers; mutation; subcutaneouspanniculitis-like T-cell lymphoma; whole-exome sequencing

Mesh：

Substances：

Year:  2017        PMID： 28294301     DOI： 10.1111/bjh.14611

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

1.  Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations.

Authors:  Jiwon Koh; Insoon Jang; Seungchan Mun; Cheol Lee; Hee Jeong Cha; Young Ha Oh; Jin-Man Kim; Jae Ho Han; Jin Ho Paik; Junhun Cho; Young Hyeh Ko; Chan-Sik Park; Heounjeong Go; Jooryung Huh; Kwangsoo Kim; Yoon Kyung Jeon
Journal:  Blood Adv       Date:  2021-10-26

Review 2.  Maximizing insights from monogenic immune disorders.

Authors:  Anis Barmada; Anjali Ramaswamy; Carrie L Lucas
Journal:  Curr Opin Immunol       Date:  2021-10-22       Impact factor: 7.486

3.  Clonotype pattern in T-cell lymphomas map the cell of origin to immature lymphoid precursors.

Authors:  Aishwarya Iyer; Dylan Hennessey; Robert Gniadecki
Journal:  Blood Adv       Date:  2022-04-12

4.  EYA2 promotes lung cancer cell proliferation by downregulating the expression of PTEN.

Authors:  Zhaoming Li; Ran Qiu; Xia Qiu; Tian Tian
Journal:  Oncotarget       Date:  2017-12-02

5.  CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma.

Authors:  Yue Song; Wei Song; Zhaoming Li; Wenting Song; Yibo Wen; Jiwei Li; Qingxin Xia; Mingzhi Zhang
Journal:  Front Oncol       Date:  2020-04-23       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.